Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

John T. Isaacs, Susan L. Dalrymple, D. Marc Rosen, Hans Hammers, Anders Olsson, Tomas Leanderson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Tasquinimod, an orally active quinoline-3-carboxamide, binds with high affinity to HDAC4 and S100A9 in cancer and infiltrating host cells within compromised tumor microenvironment inhibiting adaptive survival pathways needed for an angiogenic response. Clinical trials document that as low as 0.5-1mg tasquinimod/day is therapeutic against castrate resistant metastatic prostate cancer. Tasquinimod is metabolized via cytochrome P4503A4, but ketoconazole at a dose which completely inhibits CYP3A metabolism does not affect tasquinimod's ability to inhibit endothelial "sprouting" in vitro or anti-cancer efficacy against human prostate cancer xenografts in vivo. Tasquinimod's potency is facilitated by its reversible binding (Kd < 35 μM) to the IIA subdomain of albumin (Sudlow's site I). As blood vessels within the compromised cancer microenvironment are characterized by a higher degree of leakiness than those in normal tissues, this results in an enhanced uptake of tasquinimod bound to albumin in cancer tissue via a tumor specific process known as the "enhanced permeability and retention" (i.e., EPR) effect. Thus, despite plasma levels of < 1 μM, the EPR effect results in intracellular drug concentrations of 2-3 μM, levels several-fold higher than needed for inhibition of endothelial sprouting (IC50 ~ 0.5 μM) or for inhibition of HDAC4 and S100A9 mediated tumor growth.

Original languageEnglish (US)
Pages (from-to)8093-8106
Number of pages14
JournalOncotarget
Volume5
Issue number18
DOIs
StatePublished - Jan 1 2014

Fingerprint

Tumor Microenvironment
Albumins
Neoplasms
Prostatic Neoplasms
Cytochrome P-450 CYP3A
Ketoconazole
Cytochromes
Heterografts
Inhibitory Concentration 50
Blood Vessels
tasquinimod
Permeability
Clinical Trials
Survival
Growth
Pharmaceutical Preparations

Keywords

  • Albumin-binding
  • Drug uptake
  • EPR effect
  • Tasquinimod

ASJC Scopus subject areas

  • Oncology

Cite this

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. / Isaacs, John T.; Dalrymple, Susan L.; Marc Rosen, D.; Hammers, Hans; Olsson, Anders; Leanderson, Tomas.

In: Oncotarget, Vol. 5, No. 18, 01.01.2014, p. 8093-8106.

Research output: Contribution to journalArticle

Isaacs, John T. ; Dalrymple, Susan L. ; Marc Rosen, D. ; Hammers, Hans ; Olsson, Anders ; Leanderson, Tomas. / Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment. In: Oncotarget. 2014 ; Vol. 5, No. 18. pp. 8093-8106.
@article{39ea90e842c5497c8c293fa624f39fa0,
title = "Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment",
abstract = "Tasquinimod, an orally active quinoline-3-carboxamide, binds with high affinity to HDAC4 and S100A9 in cancer and infiltrating host cells within compromised tumor microenvironment inhibiting adaptive survival pathways needed for an angiogenic response. Clinical trials document that as low as 0.5-1mg tasquinimod/day is therapeutic against castrate resistant metastatic prostate cancer. Tasquinimod is metabolized via cytochrome P4503A4, but ketoconazole at a dose which completely inhibits CYP3A metabolism does not affect tasquinimod's ability to inhibit endothelial {"}sprouting{"} in vitro or anti-cancer efficacy against human prostate cancer xenografts in vivo. Tasquinimod's potency is facilitated by its reversible binding (Kd < 35 μM) to the IIA subdomain of albumin (Sudlow's site I). As blood vessels within the compromised cancer microenvironment are characterized by a higher degree of leakiness than those in normal tissues, this results in an enhanced uptake of tasquinimod bound to albumin in cancer tissue via a tumor specific process known as the {"}enhanced permeability and retention{"} (i.e., EPR) effect. Thus, despite plasma levels of < 1 μM, the EPR effect results in intracellular drug concentrations of 2-3 μM, levels several-fold higher than needed for inhibition of endothelial sprouting (IC50 ~ 0.5 μM) or for inhibition of HDAC4 and S100A9 mediated tumor growth.",
keywords = "Albumin-binding, Drug uptake, EPR effect, Tasquinimod",
author = "Isaacs, {John T.} and Dalrymple, {Susan L.} and {Marc Rosen}, D. and Hans Hammers and Anders Olsson and Tomas Leanderson",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2378",
language = "English (US)",
volume = "5",
pages = "8093--8106",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "18",

}

TY - JOUR

T1 - Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

AU - Isaacs, John T.

AU - Dalrymple, Susan L.

AU - Marc Rosen, D.

AU - Hammers, Hans

AU - Olsson, Anders

AU - Leanderson, Tomas

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tasquinimod, an orally active quinoline-3-carboxamide, binds with high affinity to HDAC4 and S100A9 in cancer and infiltrating host cells within compromised tumor microenvironment inhibiting adaptive survival pathways needed for an angiogenic response. Clinical trials document that as low as 0.5-1mg tasquinimod/day is therapeutic against castrate resistant metastatic prostate cancer. Tasquinimod is metabolized via cytochrome P4503A4, but ketoconazole at a dose which completely inhibits CYP3A metabolism does not affect tasquinimod's ability to inhibit endothelial "sprouting" in vitro or anti-cancer efficacy against human prostate cancer xenografts in vivo. Tasquinimod's potency is facilitated by its reversible binding (Kd < 35 μM) to the IIA subdomain of albumin (Sudlow's site I). As blood vessels within the compromised cancer microenvironment are characterized by a higher degree of leakiness than those in normal tissues, this results in an enhanced uptake of tasquinimod bound to albumin in cancer tissue via a tumor specific process known as the "enhanced permeability and retention" (i.e., EPR) effect. Thus, despite plasma levels of < 1 μM, the EPR effect results in intracellular drug concentrations of 2-3 μM, levels several-fold higher than needed for inhibition of endothelial sprouting (IC50 ~ 0.5 μM) or for inhibition of HDAC4 and S100A9 mediated tumor growth.

AB - Tasquinimod, an orally active quinoline-3-carboxamide, binds with high affinity to HDAC4 and S100A9 in cancer and infiltrating host cells within compromised tumor microenvironment inhibiting adaptive survival pathways needed for an angiogenic response. Clinical trials document that as low as 0.5-1mg tasquinimod/day is therapeutic against castrate resistant metastatic prostate cancer. Tasquinimod is metabolized via cytochrome P4503A4, but ketoconazole at a dose which completely inhibits CYP3A metabolism does not affect tasquinimod's ability to inhibit endothelial "sprouting" in vitro or anti-cancer efficacy against human prostate cancer xenografts in vivo. Tasquinimod's potency is facilitated by its reversible binding (Kd < 35 μM) to the IIA subdomain of albumin (Sudlow's site I). As blood vessels within the compromised cancer microenvironment are characterized by a higher degree of leakiness than those in normal tissues, this results in an enhanced uptake of tasquinimod bound to albumin in cancer tissue via a tumor specific process known as the "enhanced permeability and retention" (i.e., EPR) effect. Thus, despite plasma levels of < 1 μM, the EPR effect results in intracellular drug concentrations of 2-3 μM, levels several-fold higher than needed for inhibition of endothelial sprouting (IC50 ~ 0.5 μM) or for inhibition of HDAC4 and S100A9 mediated tumor growth.

KW - Albumin-binding

KW - Drug uptake

KW - EPR effect

KW - Tasquinimod

UR - http://www.scopus.com/inward/record.url?scp=84907997102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907997102&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2378

DO - 10.18632/oncotarget.2378

M3 - Article

VL - 5

SP - 8093

EP - 8106

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -